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SOX2 is a well-known core transcription factor in embryonic stem cells (ESCs) and has an important role in the maintenance of
pluripotency. Recently, SOX2 expression has also been reported in adult stem cells (ASCs), but the role of SOX2 in ASCs
remains unknown.Inthis study, weexaminedthe molecular mechanisms ofSOX2 inhuman mesenchymal stem cells (hMSCs), a
type of ASCs, by performing inhibition studies. SOX2 inhibition resulted in altered cell growth and differentiation capabilities.
These changes coincided with a decrease in Dickkopf-1 (DKK1), a soluble inhibitor of WNT signaling. Chromatin immuno-
precipitation and luciferase assays showed that SOX2 binds to DKK1 and has a positive regulatory role in transcription. The
enforced expression of DKK1 in SOX2-inhibited hMSCs reversed the differentiation deformities, but could not abrogate the cell
proliferation defect. Proliferation was regulated by c-MYC, whose expression can also be controlled by SOX2. Our study shows
that SOX2 directly regulates DKK1 expression and, as a consequence, determines the differentiation lineage of hMSCs.
Moreover, SOX2 also regulates proliferation by affecting c-MYC. Therefore, these results suggest that SOX2 might have a
speciﬁc function by regulating DKK1 and c-MYC in the differentiation and growth of ASCs, which is separate from its roles
in ESCs.
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The signaling pathways in the core transcriptional network of
embryonic stem cells (ESCs) have previously been well
described.
1 Several core ESC transcription factors are also
expressed in human mesenchymal stem cells (hMSCs).
2,3
Octamer-binding transcription factor 4 (OCT4) is a POU
domain-containing transcription factor, known to be essential
for the stemness and pluripotency of ESCs.
4 OCT4A has
conserved roles in ESCs and in human umbilical cord blood-
derived MSCs (hUCB–MSCs).
5 OCT4 interacts with sex-
determining region Y-box 2 (SOX2), and genome-wide
mapping of OCT4- and SOX2-binding sites in human ESCs
shows that they co-target multiple genes.
6 The cis-regulatory
element to which the SOX2–OCT4 complex is bound consists
of neighboring SOX (50-CATTGTT-30) and OCT (50-ATGCAA
AT-30) elements.
7 Indeed, SOX2 was reported to be indis-
pensable for the maintenance of ESC pluripotency,
8 and
ESCs from Sox2-null mice primarily differentiate into trophec-
toderm-like cells.
9 Microarray analysis has shown that SOX2
regulates multiple transcription factors that affect the OCT4
expression.
10 SOX2 expression has been detected in ESCs
and in several tissues derived from hMSCs, including adipose
tissue, dermis, heart,
2 and neural tissue.
11 An integrated
expressionproﬁle andchromatin immunoprecipitation(ChIP)-
sequencing analysis showed that SOX2 is involved in the
BMP signaling pathway, steroid metabolic processes, histone
modiﬁcations, and many receptor-mediated signaling
pathways, such as IGF1R and ITPR2.
12 The well-known
oncogene c-MYC is also an important transcription factor in
ESCs.Manygenesareregulatedbyc-MYCandconsequently
induce cell proliferation. Deregulation of c-MYC contributes to
the genesis of most human tumors.
13 Our previous study has
shown that c-MYC is closely connected with the proliferation
and epigenetic regulation of hMSCs.
14 Moreover, a recent
study has demonstrated a hypothetical relationship between
c-MYC and SOX2.
15
WNT genes, a family of 19 genes in humans and mice,
produce secreted proteins that are involved in cell prolifera-
tion, differentiation, and apoptosis. These genes are also
crucial for embryonic tissue development and adult tissue
regeneration.
16 Canonical WNT/b-CATENIN signaling is
important for the stemness and differentiation of stem cells.
17
The addition of Dickkopf-1 (DKK1), an antagonist of WNT
signaling, allows hMSCs to re-enter the cell cycle by inhibiting
the canonical WNT/b-CATENIN-signaling pathway.
18 The
secretion of DKK1 by hMSCs inhibits the growth of breast
cancer cells.
19 The presence of DKK1 triggers a disruption in
the canonical WNT cascade and results in the inhibition of
hMSC osteogenesis.
20 DKK1 is transiently upregulated in the
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WNT cascadeis important for the adipogenic differentiation of
hMSCs.
21 SOX factors appear to modulate b-CATENIN/TCF
activity through a variety of mechanisms, including protein–
protein interactions, DNA binding, recruitment of cofactors, and
protein stability.
22 SOX2 and b-CATENIN act synergistically in
the transcriptional regulation of CCND1in breast cancer cells.
23
RecentstudieshavedemonstratedthatSOX2contributestothe
inhibition of WNT signaling and regulates osteoblast differentia-
tion.
24,25 However, SOX2 does not bind to TCF/LEF in human
cells (Ingenuity Systems, Redwood City, CA, USA), and how
WNT signaling is regulated by SOX2 is still unknown.
Previous studies have shown that SOX2 is expressed in
several types of adult stem cells (ASCs), including neural
stem cells (NSCs),
26 dermal stem cells,
27 and germline stem
cells.
28However,theonlyknownroleofSOX2isinNSCs,and
relates to the self-renewal and neuronal differentiation of
NSCs.
26 The transcriptomes of NSCs, ESCs, and ASCs are
quite different from each other.
29,30 Therefore, SOX2 may
have different roles in each type of stem cell.
Results
SOX2 is expressed in hUCB–MSCs, and cell growth is
altered after SOX2 inhibition in hUCB–MSCs. To
investigate the role of SOX2 in hMSCs, we examined
SOX2 expression. Three well-known types of hMSCs
(hUCB–MSCs, human adipose tissue-derived MSCs (hAD–
MSCs), and human bone-marrow derived MSCs (hBM–
MSCs)) were tested. Tera-1, an embryonic carcinoma cell
line, was used as a positive control for SOX2 expression.
SOX2 expression was found in hUCB–MSCs, although the
levels were lower than in the tera-1 cells (Figure 1a). To
quantify the SOX2 expression levels in hMSCs, quantitative
reverse transcription PCR (RT-PCR) was performed
(Figure 1b). hUCB–MSCs exhibited higher SOX2
expression than the other hMSCs analyzed. Furthermore,
immunocytochemistry conﬁrmed the nuclear localization of
SOX2 in tera-1 cells and hUCB–MSCs (Figure 1c).
Fibronectin staining was performed to determine the
morphology of the cells. In the tera-1 cells, SOX2 was
highly expressed in the nucleus and colocalized with
Hoechst. SOX2 expression was also detected in the
nuclear region of hUCB–MSCs (Supplementary Figure 1a).
However, no detectable signals were observed in the
nucleus or cytoplasm of hAD–MSCs or hBM–MSCs.
Because SOX2 expression in hAD– and hBM–MSCs was
so low, we conﬁrmed whether all three types of hMSCs
retained pluripotency. Western blotting for SOX2 and other
stem cell markers such as OCT4 and c-MYC was performed
using nuclear and cytoplasmic extracts (Supplementary
Figure 1b). Although the levels were lower than in hUCB–
MSCs, SOX2 and OCT4 could be detected in hAD– and
hBM–MSCs.
Toinvestigate the role of SOX2, knockdown was performed
in hUCB–MSCs using short hairpin RNA-producing lentivirus.
The sh-SOX2 construct targets the 30-untranslated region
of SOX2. A non-targeting, random sequence-inserted lenti-
virus was used as a control. SOX2 knockdown (sh-SOX2) in
hUCB–MSCs caused a decrease in cell proliferation compared
with the sh-control (Figures 1d and g). These proliferation
rates correlated with SOX2 expression levels after lentiviral
infection (Figure 1e). The cell cycle was also analyzed by
ﬂuorescence-activated cell sorting (FACS) in both the sh-SOX2-
and sh-control-treated cells (Figure 1f). After sh-SOX2 treat-
ment, the proportion of cells in G0/G1 increased, and the
portion of cells in S phase decreased, compared with the
sh-control. To conﬁrm this phenotype, another SOX2 knock-
down study was designed using a commercially available,
speciﬁc siRNA for SOX2 inhibition (si-SOX2) and a non-
targeting random sequence-inserted siRNA as a control
(si-control). At 48h after siRNA transfection, the cells treated
with si-SOX2 displayed growth retardation compared with
si-control-treated cells (Supplementary Figure 2a). By FACS
analysis and MTT assays, the si-SOX2 treatment caused a
decrease in S-phase composition (Supplementary Figure 2c)
and a decrease in the proliferation rate (Supplementary Figure 2d).
Differentiation ability is altered after SOX2 inhibition. To
validate the role of SOX2 in the differentiation of hUCB–
MSCs, adipogenic, osteogenic, and chondrogenic
differentiation studies were performed. After 2 weeks of
adipogenic induction, a decreased number of oil droplets
were found in sh-SOX2 compared with the sh-control-treated
cells (Figure 2a). The optical density of oil red O after elution
conﬁrmed the morphological observations (Figure 2b).
Molecular markers of adipogenic differentiation, PPAR-g
and C/EBP-b, were analyzed by RT-PCR (Figure 2c). The
relative expression of PPAR-g and C/EBP-b decreased in
sh-SOX2 cells, compared with their levels in sh-control cells.
An adipogenic differentiation assay was also conducted using
cells transiently inhibited with siRNAs. Differentiation was
initiated 48h after of siRNA transfection and continued for
2 weeks. The cells treated with si-SOX2 manifested a
decreased level of lipid droplet staining (Supplementary
Figures 3a–c). However, the decrease in adipogenesis was
greater in the hUCB–MSCs treated with the sh-SOX2
lentivirus. There was no difference in the elution of oil red
O between the si-control and si-SOX2 conditions
(Supplementary Figure 3b). The molecular markers of
adipogenic differentiation were decreased. These results
show that the long-term inhibition of SOX2 by lentivirus led to
more severe effects on the adipogenesis of hUCB–MSCs
than transient inhibition with siRNA.
After 2 weeks of osteogenic induction, alizarin red S
staining was performed (Figures 2d and e). In contrast to
adipogenesis, the osteogenic differentiation ability was
increased by the sh-SOX2 treatment, compared with the
sh-control. The expression of osteogenic molecular markers,
COL1A2 and VDR, was increased in sh-SOX2 compared with
sh-control-treated cells (Figure 2f). In the transient SOX2
inhibition study, there were small differences between the
si-control and si-SOX2 conditions after 2 weeks of osteogenic
differentiation. Alizarin red S staining was nearly identical
(Supplementary Figures 3d–f), but the levels of COL1A2 and
VDR were increased in si-SOX2-treated cells compared with
the si-control (Supplementary Figure 3f).
After 2 weeks of chondrogenic induction, hUCB–MSCs
aggregated and formed a pellet (Figure 2g). The pellet formed
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Cell Death and Differentiationby the sh-SOX2-treated cells was larger than the sh-control.
For histological evaluation, the pellets were cut into serial
3mm sections and stained with toluidine blue (Figure 2h).
Toluidine blue-stained sections showed that sh-SOX2 cells
formed larger pellets than the sh-control. The expression of
chondrogenic markers, SOX9 and AGGRECAN, was
increased in sh-SOX2 compared with the sh-control-treated
cells (Figure 2i). The same results were obtained using
transient siRNA inhibition as in the lentivirus-mediated
inhibition study (Supplementary Figures 3g–i). These results
Figure 2 Differentiation abnormalities after SOX2 knockdown in hUCB–MSCs. (a–c) Adipogenic differentiation analysis after SOX2 knockdown with the lentiviral vector.
(a)Thenumberofoil redO-stainedlipiddropletsdecreasedafterSOX2 knockdown.Thescale bar represents100mm. (b)Elutionof oilred Omanifestedreducednumbersof
lipid droplets in SOX2-knockdown hUCB–MSCs. ***Po0.001. (c) The expression of adipogenic markers decreased after SOX2 knockdown. (d–f) Osteogenic differentiation
analysis after SOX2 knockdown with the lentiviral vector. (d) The alizarin red S-stained hUCB–MSC population increased after SOX2 knockdown. The scale bar represents
100mm. (e) The elution of alizarin red S increased after SOX2 knockdown. ***Po0.001. (f) The expression of osteogenic markers increased after SOX2 knockdown. (g–i)
ChondrogenicdifferentiationafterSOX2knockdownwiththelentiviralvector.(gandh)Themaximaldiametersofsh-SOX2cellswerelargerthanthoseof thesh-controlcells.
The scale bar represents 100mm. (i) The expression of chondrogenic markers increased after SOX2 knockdown
Figure 1 Analysis of SOX2 expression and proliferation in hMSCs. (a) RT-PCR of SOX2 in tera-1, hUCB–MSCs (UCB), hAD–MSCs (AD), and hBM–MSCs (BM). SOX2
expression in hUCB–MSCs was lower than in tera-1 cells. (b) Real-time PCR of SOX2 in hMSCs. The expression of SOX2 in hUCB–MSCs was higher than in other hMSCs.
(c) Immunocytochemistry of SOX2. SOX2 expression in the nucleus was found in tera-1 cells and hUCB–MSCs. The scale bar represents 10mm. (d) The hUCB–MSC
population decreased after SOX2 knockdown. The scale bar represents 100mm. (e) SOX2 expression decreased by 10% of the sh-control value after SOX2 knockdown by
lentivirus infection. (f) The proportion of cells in S and G0/G1 phase decreased and increased, respectively, after SOX2 knockdown. (g) Cell proliferation signiﬁcantly
decreased after SOX2 knockdown, as indicated by the MTT assays. *Po0.05; **Po0.01; ***Po0.001
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and chondrogenesis in hUCB–MSCs.
DKK1 expression decreases in SOX2-inhibited hUCB–
MSCs. To determine the molecular targets of SOX2 in
hUCB–MSCs, a PCR array was performed (Figures 3a, b
and Supplementary Table 2). The expression of the 88
most-cited genes in stem cells was surveyed. Among them,
the expression of AXIN1 (one of the canonical WNT/b-
CATENIN-signaling genes) was increased by 5.2-fold
after sh-SOX2 treatment, compared with the sh-control.
To understand the regulation of WNT-signaling genes
by SOX2 in greater detail, the levels of key components of
the WNT signaling pathway (DKK1, DKK4, FZD1, FZD2,
FRAT1, FRAT2, b-CATENIN, LRP5, and LRP6) were
examined (Figure 3c). The levels of most WNT signaling-
related genes did not change or were only slightly altered
after sh-SOX2 treatment, compared with the sh-control.
However, the most signiﬁcant change was found in DKK1
expression; expression was signiﬁcantly decreased by
sh-SOX2 compared with the sh-control. The expression of
b-CATENIN was increased by sh-SOX2 compared with
the sh-control. Levels of phosphorylated b-CATENIN were
reduced by sh-SOX2 compared with the sh-control
(Figure 3d). To conﬁrm the regulation of WNT by SOX2,
a TOP/FOP FLASH assay was performed (Figure 3e).
The sh-SOX2 treatment resulted in an eight-fold increase
in TOP FLASH luminescence, compared with the sh-control.
In case of transient inhibition, the expression levels of
WNT signaling-related genes were similar to those observed
upon lentivirus-mediated inhibition of SOX2 (Supplementary
Figure 3 SOX2 knockdown alter WNT signaling through DKK1. (a and b) PCR array results. The expression of 88 frequently cited stem cell genes were compared
between sh-control and sh-SOX2 cells. The expression of AXIN1, KRT15, and GJB2 increased by more than four-fold, and the expression of c-MYC, PARD6A, and CDH1
decreasedby more than four-fold afterSOX2 knockdown. (c) Real-timePCR analysisof WNT-related candidategenes. The expression of DKK1was signiﬁcantly decreased,
but the expression of b-CATENIN was increased after SOX2 knockdown. *Po0.05; **Po0.01. (d) The western blot indicates reduced phosphorylated b-CATENIN
(p-b-CATENIN) expression and increased total b-CATENIN (total-b-CATENIN) expression after SOX2 knockdown in hUCB–MSCs. Protein levels were normalized to
b-ACTIN using Image J analysis software. (e) The TOP/FOP Flash assay shows increased WNT signaling in sh-SOX2 cells. ***Po0.001
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Cell Death and DifferentiationFigures 4a and b). Moreover, the expression of TOP FLASH
was increased by the si-SOX2 treatment (Supplementary
Figure 4c). Therefore, DKK1 is suggested as a strong
candidate gene that is regulated by SOX2 in hUCB–MSCs.
SOX2 directly binds to the DKK1 promoter region and
activates DKK1 expression. The SOX family proteins
possess a DNA-binding HMG domain and additional
activation or repression domains that are implicated in
transcriptional regulation.
31 The evolutionarily conserved
region of DKK1 was determined using database searches
(UCSC genome browser, human genome March 2006
assembly, http://genome.ucsc.edu/). The human genome
sequence surrounding the DKK1 transcriptional start
site, from 5kbps upstream to 5kbps downstream, was
searched. We found that the exons and the promoter
region around 1kbps upstream are highly conserved in
mammalian genomic DNA (Figure 4a). SOX2 typically binds
50-CTTTGTT-30 or 50-CATTGTT-30 sequences,
31 and one
SOX2-binding motif was identiﬁed at  76bps (Figure 4a).
To determine whether SOX2 binds to the DKK1 promoter
region, a ChIP assay was performed. Tera-1 was used as a
positive control, because SOX2 is highly expressed in tera-1
cells. SOX2 bound DKK1 in sh-control-treated cells. The
signal disappeared in sh-SOX2-treated cells, and the same
result was observed using siRNA-mediated inhibition
(Figure 4b and Supplementary Figure 5a).
To examine SOX2 activity at the DKK1 promoter, the
human genome fragment from  974bps to þ119bps around
the DKK1 transcription start site was cloned into the
luciferase-enhancer vector (Figure 4c). This region contains
a predicted SOX2-binding site (B), which was conﬁrmed by
ChIP. The sh-SOX2 treatment resulted in signiﬁcantly lower
luciferase activity than the sh-control when transfection and
luciferase activities were normalized to the SV40-promoter
control vector (Figure 4d). To verify these results, SOX2
inhibition by siRNA in hUCB–MSCs was also tested. The si-
SOX2 treatment resulted in signiﬁcantly lower luminescence
than the si-control (Supplementary Figure 5b). These results
provided evidence that DKK1 expression is positively regu-
lated by SOX2, and that DKK1 is a direct SOX2-target gene.
To conﬁrm the SOX2 binding at the DKK1 promoter, the
luciferase assay was performed using mutated constructs
(Figure 4e). Plasmid M1 has a single point mutation; the
Figure 4 SOX2directlybindstotheDKK1promoterregion.(a)Sequencehomologyof regionaroundDKK1betweenmammals.Exceptfor theexonsofDKK1, theregion
1kbps upstream of the transcriptional start site of DKK1 was highly conserved and contained an HMG homeodomain ( 76bps). (b) ChIP assay for the  76bps region of
DKK1 showed SOX2-speciﬁc binding. (c) Luciferase reporter assay. Luciferase activity and transfection efﬁciency were normalized to transfection of the SV40 promoter
control vector (SV40 promoter). The human DKK1 promoter region from  974bps to þ119bps around the DKK1 transcription start site, which contains an HMG-binding
domain, was cloned into the luciferase enhancer vector (DKK1 promoter). (d) The luciferase activity of sh-SOX2 was signiﬁcantly decreased compared with that of the
sh-control. ***Po0.001. (e) Site-directed mutagenesis, involving single (M1) and triple (M3) mutations, was performed in the HMG domain of the DKK1 promoter vector.
(fandg)TheM1(alsoSOX2bindingsite)mutationhadnoeffectontheluciferaseactivity,buttheM3mutationsigniﬁcantlyreducedtheluciferaseactivityinbothhUCB–MSCs
and tera-1 cells. ***Po0.001
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Cell Death and Differentiationsecond ‘T’ in the HMG domain-binding region was substituted
with an ‘A’. M1 is also the SOX2-binding sequences. Plasmid
M3 has three point mutations in which the middle ‘TGT’ was
substituted with ‘CAG’. Normal hUCB–MSCs and tera-1 cells,
which were not treated with lentivirus or siRNA, were used for
detectingluciferaseactivity(Figures4fandg).M1-transfected
cellshadsimilarluminescenceactivitycomparedwiththenon-
mutated DKK1 promoter vector-transfected cells. However,
M3-transfected hUCB–MSCs and tera-1 cells showed sig-
niﬁcantly decreased luminescence, compared with the con-
trol. These results demonstrated that the binding of SOX2 to
the HMG domain of DKK1 directly regulates the transcription
of DKK1.
Ectopic expression of DKK1 in SOX2-knockdown hUCB–
MSCs recovers the differentiation malformations. A
DKK1 rescue experiment in SOX2-inhibited hUCB–MSCs
was performed to validate the role of DKK1 in SOX2-
expressing hMSCs. The adipogenic differentiation ability
increased after the ectopic expression of DKK1 in sh-SOX2-
treated cells (Figure 5a). Elevated optical density after elution
of oil red O was also increased by the ectopic expression of
DKK1 in sh-SOX2-treated cells (Figure 5b), and the
expression of adipogenic marker genes was altered. The
expression of PPAR-g and C/EBP-b increased after ectopic
DKK1 expression in sh-SOX2-treated cells (Figure 5c). The
osteogenic and chondrogenic ability of SOX2 knockdown
Figure 5 Ectopic expression of DKK1 in SOX2-knockdown hUCB–MSCs reverted the differentiation malformation. (a–c) The adipogenic deformity of lentiviral-mediated
SOX2-knockdown hUCB–MSCs was rescued after ectopic expression of DKK1, and this result was conﬁrmed by morphology (a), oil red O elution (b), and marker gene
analysis (c). The scale bar represents 100mm. **Po0.01. (d–f) The ability of hUCB–MSCs to undergo osteogenic differentiation upon SOX2 knockdown by lentivirus was
decreased after the ectopic expression of DKK1, and this result was conﬁrmed by morphology (d), alizarin red S elution (e), and marker gene analysis (f). The scale bar
represents 100mm. ***Po0.001. (g and h) The ability of hUCB–MSCs to undergo chondrogenic differentiation upon SOX2 knockdown by lentivirus was decreased by the
ectopic expression of DKK1, and this result was conﬁrmed by pellet size (g) and marker gene analysis (h). The scale bar represents 100mm
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Cell Death and DifferentiationhUCB–MSCs decreased after the ectopic expression of
DKK1 (Figures 5d–h). The number of alizarin red S-stained
cells decreased after ectopic expression of DKK1 in
sh-SOX2-treated cells, and these results were conﬁrmed by the
elution of alizarin red S (Figures 5d and e). The expression of
osteogenic markers (COL1A2 and VDR) decreased after the
ectopic expression of DKK1 in sh-SOX2-treated cells
(Figure 5f). Chondrogenesis also decreased after ectopic
DKK1 expression in SOX2-knockdown hUCB–MSCs (Figures
5g and h). Therefore, DKK1 expression, which is regulated
by SOX2, affects the differentiation ability.
c-MYC, not DKK1, is responsible for the proliferation
defect of SOX2-inhibited hUCB–MSCs. Cellular proliferat-
ion was examined to determine whether DKK1 could rescue
not only the differentiation changes, but also the proliferation
defect in SOX2-knockdown hUCB–MSCs. However, unlike
the differentiation results, the decreased proliferation in sh-
SOX2-treated cells was not recovered by the ectopic
expression of DKK1 (Figures 6a and b). Moreover, identical
results were obtained using both lentiviral and siRNA
inhibition studies (Supplementary Figures 6a and b). To
determine whether the addition of WNT ligand could rescue
the growth inhibition observed in hUCB–MSCs when SOX2
is downregulated, WNT3A and WNT5A, regarded as
canonical and non-canonical WNT ligands, respectively,
were added to the growth media. The portion of the SOX2-
inhibited cells treated with WNT ligand in S phase of the cell
cycle increased after 24h, but there was no change in cell
proliferation in response to the WNT3A or WNT5a (Figures
6c, d and Supplementary Figures 6c, d). To conﬁrm the
reason of discordance between cell cycle and proliferation
test, cell cycle was checked in a time-dependent manner with
WNT3A. The results showed that WNT3A inﬂuenced cell
cycle in a moment, but could not maintain the increased level of
S phase consistently until 3 days (Supplementary Figure 6e).
One of the candidate genes was the transcription factor
c-MYC. Although c-MYC is regulated by b-CATENIN/TCF
signaling,
32 the expression of c-MYC was dramatically
reduced in SOX2-knockdown hUCB–MSCs (Figure3b and
Supplementary Table 2). SOX2-knockdown hUCB–MSCs
exhibited decreased c-MYC expression in western blot
(Figure 7a and Supplementary Figure 7). To evaluate the
role of c-MYC in SOX2-knockdown hUCB–MSCs, enforced
expression of c-MYC using a retroviral vector was performed
in sh-SOX2-treated cells (sh-SOX2 þ c-MYC). A GFP
expression retrovirus was used as a vector control (VC). To
quantify c-MYC expression, RT-PCR was performed
(Figure 7b). The enforced expression of c-MYC in sh-SOX2
cells resulted in higher expression of c-MYC than in the
VC-infected sh-SOX2 cells, and the proliferation was in-
creased after enforced c-MYC expression (Figure 7c). Cell
cycle analysis showed that the enforced expression of c-MYC
in sh-SOX2 cells caused an increase in S-phase composition
(Figure 7d). Moreover, the MTT assay showed that the
enforced expression of c-MYC in sh-SOX2 cells resulted in
higher proliferation than the VC-infected sh-SOX2 cells
(Figure 7e). Therefore, it was suggested that c-MYC expres-
sion, regulated by SOX2, was responsible for the growth of
hUCB–MSCs.
Discussion
SOX2 is expressed in hUCB–MSCs although the levels were
very low compared with the levels in tera-1 cells. Never-
theless, hUCB–MSCs exhibited stronger expression of SOX2
compared with hBM–MSCs and hAD–MSCs, which have
been previously reported to express SOX2.
2,33 SOX2 inhibi-
tion in hMSCs resulted in retarded cell growth, depressed
adipogenic differentiation ability, and enhanced osteo-chon-
drogenic differentiation ability. In hMSCs, SOX2 bound to the
promoter region of DKK1 and positively regulated DKK1
transcription. Ectopic expression of DKK1 in SOX2-inhibited
hMSCs rescued the differentiation defects, but could not
revert the proliferation defects caused by SOX2 inhibition.
This proliferation defect was reduced by the additional
expression of c-MYC in SOX2-inhibited hMSCs (Figure 8).
The levels of SOX2 expression were variable among the
three types of hMSCs. Our previous studies have proven
that all three types of hMSCs exhibited self-renewability and
multi-lineage differentiation potential.
3,14,34 There were no
Figure 6 Ectopic expression of DKK1 and WNT ligands cannot recover the
proliferation defect caused by SOX2 knockdown in hUCB–MSCs. (a and b)
Proliferation of hUCB–MSCs with lentiviral SOX2 knockdown did not increase after
DKK1 treatment, as conﬁrmed by the MTT assays and FACS analysis. *Po0.05;
**Po0.01; ***Po0.001. (c and d) Treatment with WNT3A and WNT5A could not
recover the proliferation defect in SOX2-knockdown hUCB–MSCs. **Po0.01;
***Po0.001
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Cell Death and Differentiationcharacteristic differences among these hMSCs. The reason
for the differential SOX2 expression might arise from the
hMSCs source. The hUCB–MSCs were obtained from the
blood of newborns, but the hAD–MSCs and hBM–MSCs were
collected from adult donors that were greater than 20 years
old. Therefore, the hUCB–MSCs were considered more
primitive than the other hMSCs.
The differentiation of hMSCs can be divided into two steps:
the differentiation fate-decision step (early) and the fully
differentiated step (late). Transient inhibition of SOX2 with
siRNA permitted us to determine the effect of SOX2 on the
early fate-decision step, and the lentivirus-mediated SOX2
knockdown allowed us to determine the effect of SOX2 on
both steps of the hMSC differentiation process. In this study,
the differentiation defects observed in SOX2 siRNA-inhibited
hMSCs wereless severe than thedefects observed in hMSCs
treatedwith sh-SOX2lentivirus. Therefore, theeffect ofSOX2
on the differentiation of hMSCs occurred during the full
differentiation process. Canonical WNT signaling is a me-
senchymal regulatory factor that provides instructive cues for
the recruitment, maintenance, and differentiation of MSCs.
35
Once MSCs are committed to the osteogenic lineage,
canonical WNT signaling stimulates osteogenic differentia-
tion. Canonical WNT signaling is also likely to promote the
initiation of chondrogenesis via crosstalk with TGF-b signal-
ing.
36 WNT/b-CATENIN signaling inhibits adipogenic
differentiation and enhances chondrogenic differentiation.
37
Therefore,thedecreasedadipogenicabilityofSOX2-inhibited
hMSCs after adipogenic induction was due to the activation of
canonical WNT signaling, which occurred through DKK1
suppression in response to SOX2 knockdown.
SOX2 has an essential role in maintaining ESC pluripo-
tency.
38 A previous study has shown that SOX2-null ESCs
differentiated into trophoectoderm-like cells within 72h.
9
These previous results are similar to our current data using
hUCB–MSCs in that, SOX2 regulates the differentiation of the
stem cells. However, there are several differences between
ESCs and hUBC–MSCs. SOX2 is not highly expressed in
hUCB–MSCs compared with ESCs. Therefore, SOX2 inhibi-
tionalonecouldnotinducethedifferentiationofhUCB–MSCs.
When hUCB–MSCs are induced toward a speciﬁc differentia-
tion pathway, the hUCB–MSCs differentiate into the induced
lineages speciﬁcally.
Figure 7 Enforced expression of c-MYC can recover the proliferation defects in SOX2-knockdown hUCB–MSCs. (a) The levels of c-MYC and SOX2 were reduced
after SOX2 knockdown. LAMIN A and b-ACTIN were used as loading controls. (b) The enforced expression of c-MYC was conﬁrmed by RT-PCR. (c–e) The proliferation of
SOX2-knockdown hUCB–MSCs was restored by the addition of c-MYC. The scale bar represents 100mm. ***Po0.001
Figure 8 Schematic diagram of proposed mechanism for regulatory roles of
SOX2 in hMSCs. SOX2 bound DKK1 promoter region and induced DKK1
transcription. DKK1 regulates differentiation of hMSCs, but could not control
proliferation. Proliferation was inﬂuenced by c-MYC, which was controlled by SOX2
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39 SOX2
promotes proliferation by facilitating the G1/S transition and
by transcriptional regulation of the CCND1 gene.
23 DKK1 is a
negative regulator of the WNT signaling pathway that
enhances the proliferation of many types of stem cells.
40 In
this study, the knockdown of SOX2 in hMSCs caused a
reduction in the proliferation rate, although DKK1 levels were
also decreased. Ectopic treatment of SOX2-knockdown
hMSCs with DKK1 caused more severe proliferation defects.
These results indicated that the growth of hUCB–MSCs was
controlled by factors beyond WNT signaling. c-MYC is a well-
known transcription factor and serves as a growth regulator in
cell lines, including the hMSCs.
14 The current study provides
substantial evidence that c-MYC regulates proliferation and is
regulated by SOX2 expression, although it is not clear
whether SOX2 directly regulates c-MYC expression.
ThisstudyhighlightstwofacetsofSOX2function,whichare
the differentiation and proliferation of hMSCs. The molecular
mechanism by which the loss of SOX2 induces differentiation
has been explored in these studies. DKK1 was shown to be a
direct transcriptional target of SOX2 in hMSCs, which had
never before been determined. The expression of SOX2 in
hMSCs is also important for the proliferation and multipotency
of hMSCs, largely through the regulation of DKK1 and c-MYC
expression, which is quite different from its role in ESCs. This
mechanism may be sustained in other ASCs, which exhibited
similar levels of SOX2 expression. These results provide a
novel function and mechanism for SOX2 in ASC differentia-
tion, and will serve as an important guide for further clinical
researchonhMSCsandforthedevelopmentalstudyofASCs.
Materials and Methods
Cell culture. hUCB–MSCs, hAD—MSCs, and hBM–MSCs were isolated and
cultured as previously described.
34 Brieﬂy, hUCB–MSCs were obtained from
umbilical cord blood immediately after full-term delivery with written consent from
20- to 30-year-old mothers. The hUCB–MSCs were maintained in endothelial cell
growth medium-2 (Lonza, Basel, Switzerland) containing 10% fetal bovine serum
(FBS). hAD–MSCs were isolated from freshly excised mammary fat tissue acquired
from the BaRam Plastic Surgery Hospital. The tissues were obtained from 20- to
30-year-old women during reduction mammoplasty. The hAD–MSCs were
maintained in K-SFM medium supplemented with 2mM N-acetyl-L-cysteine
(Sigma-Aldrich, St. Louis, MO, USA) and 0.2mM L-ascorbic acid (Sigma-Aldrich).
hBM–MSCs were isolated from healthy donors and were cultured in low glucose
Dulbecco’s modiﬁed Eagle’s medium (DMEM) supplemented with 10% FBS,
without any additional growth factors. The isolation and research use of hUCB–
MSCs, hAD—MSCs, and hBM–MSCs were approved by the Boramae Hospital
Institutional Review Board with written consent. All procedures were approved by
the Institutional Review Board of Seoul National University (hUCB–MSC number
0603/001–002; hAD–MSC number 0600/001–001; hBM–MSC number 0910/001–
003). The tera-1 cell line was purchased from ATCC (HTB-105, Manassas, VA,
USA)andmaintainedinDMEMlow-glucosemedium(GibcoBRL,GrandIsland,NY,
USA) containing 10% FBS (Gibco BRL).
Transfection. Lentiviruses were generated using the ViraPower Lentiviral
packaging mix (Invitrogen, Carlsbad, CA, USA). Lipofectamine 2000 (Invitrogen)
was used to transfect 293FT cells (Invitrogen) with SHDNAC-TRCN0000003253
(sh-SOX2) and SHC002 (sh-control, random sequence inserted; Sigma). The cells
were transfected with SOX2 short hairpin RNA-producing lentiviruses at an
multiplicity of infection of 5–10. Polybrene (Sigma) was added to the cell culture
medium at a ﬁnal concentration of 6mg/ml, and the cell culture medium was
replaced with fresh culture medium the day after transfection. For selection,
puromycin was added to the culture at a ﬁnal concentration of 5mg/ml for 5 days.
Retroviruses were used for c-MYC overexpression. The 293FT (Invitrogen) cells
were transfected with VSV-G, gag/pol (Sigma), and the c-MYC expression vector
(c-MYC, pMXs-hc-MYC; Addgene, Cambridge, MA, USA) or the GFP VC (Cell
biolabs, San Diego, CA, USA) using Lipofectamine 2000 (Invitrogen). Forty-eight
hours later,thesupernatantwas collectedand ﬁltered.The sh-controland sh-SOX2
cells were transfected with virus containing the c-MYC expression or GFP control
vector with polybrene at a ﬁnal concentration of 6mg/ml (Sigma).
Transient transfection assays were performed using commercially available,
speciﬁc siRNAs against SOX2 (si-SOX2) and a non-targeting control siRNA
(si-control) (ON Target plus SMARTpool, Dharmacon, Lafayette, CO, USA). The
siRNA transfections were performed according to the manufacturer’s instructions.
The cells were incubated with 30nM siRNA for 48h. After inhibition, sequential
experiments were performed for genetical and characterization analyses.
TheDKK1recoveryassaywasconductedusingaDKK1plasmidvector(number
SC303946; OriGene Technologies, Rockville, MD, USA) and a control vector
(number PCMV6XL5; OriGene Technologies). The plasmid transfections were
performed according to the manufacturer’s instructions. The cells were incubated
with 2mg of plasmid per well of a six-well plate for 48h. After infection, sequential
experiments were performed for genetic and differentiation analyses.
RT-PCR andreal-timePCR. Total RNAwas isolated fromcells usingTRIzol
reagent following the protocol provided by the manufacturer (Invitrogen). Total RNA
was used for cDNA synthesis using the Superscript III First-Strand Synthesis
System (Invitrogen). For the PCR array, the RT2 Proﬁler Stem Cell PCR Array
(catalog number PAHS-405; SuperArray, Frederick, MD, USA) was used according
tothemanufacturer’sprotocol.ForRT-PCR,cDNAandprimerswerecombinedwith
a PCR premix (Bioneer, Sung Nam, Republic of Korea). Real-time PCR was
performed by mixing cDNA with primers, and Power SYBR Green PCR Master Mix
(Applied Biosystems, Foster City, CA). Real-time PCR was performed using an ABI
7500 Real-time PCR System with supplied software (Applied Biosystems),
according to the manufacturer’s instructions. RNA expression levels were
compared after normalization to endogenous GAPDH. The primer sequences
used in this study are listed in Supplementary Table 1.
Immunocytochemistry. The cells were ﬁxed in 4% paraformaldehyde for
10min at room temperature. The cells were permeabilized by exposure to 0.5%
Triton X-100 for 10min at room temperature and were blocked for 2h with 10%
normalgoatserum(Zymed,SanFrancisco,CA,USA)atroomtemperature.Primary
antibodies were used at the manufacturer’s recommended dilution in 5% normal
goat serum. Rabbit anti-SOX2 (number ab5603, Millipore, Billerica, MA, USA) and
mouse anti-ﬁbronectin (number ab6328; Abcam, Cambridge, MA, USA) were used
for immunostaining. Fibronectin staining was utilized for cytological observation.
The secondary ﬂuorescence conjugated antibodies, goat anti-mouse Alexa Fluor
488, and goat anti-rabbit Alexa Fluor 594 (Invitrogen), were each used at a 1:1000
dilution. Hoechst (Sigma-Aldrich) was used for counterstaining.
MTT cell proliferation assay and FACS assay. The proliferation
potential was measured using the MTT assay, which is based on the ability of live
cells to convert tetrazolium salt into purple formazan. Brieﬂy, the cells (1 10
4 cells
per well) were seeded in 24-well microplates in 450ml media. After 48h, 50mlo f
MTT stock solution (5mg/ml; Sigma) was added to each well, and the plates were
furtherincubatedfor4hat 371C.Thesupernatantwasremoved,and200ml DMSO
was added to each well to solubilize the water-insoluble purple formazan crystals.
The absorbance at a wavelength of 540nm was measured with an EL800
microplate reader (BIO-TEK Instruments, Winooski, VT, USA).
The DNA content was determined by propidium iodide staining intensity. The
cells were ﬁxed with ice-cold 70% ethanol at 41C for 1h. Following ﬁxation, 50mg/ml
propidium iodide (Sigma-Aldrich) and 100mg/ml RNase A (Invitrogen) were added at
371C for 1h. Cell cycle analysis was performed using a FACS Calibur instrument
(Becton–Dickinson Pharmingen, San Jose, CA, USA) equipped with ModFit LT (Verity
Software House, Topsham, ME, USA).
In-vitro differentiation assays. To induce adipogenic and osteogenic
differentiation, hMSCs were treated as previously reported.
3 Brieﬂy, the cells
were treated with an adipogenic induction medium (DMEM supplemented with
10% FBS, 200mM indomethacin, 1mM dexamethasone, 0.5mM isobutyl
methylxanthine, and 0.5mg/ml insulin) or an osteogenic induction medium
(DMEM containing 10% FBS, 100nM dexamethasone, 50mM ascorbic acid
2-phosphate, and 10mM b-glycerophosphate; Sigma-Aldrich). After 2 weeks of
induction, the cells were stained to conﬁrm that differentiation occurred. For
adipogenic differentiation, the cells were stained with oil red O (Sigma-Aldrich).
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measured at 500nm, using a spectrophotometer. For osteogenic differentiation,
alizarin red S staining was performed. The release of solubilized alizarin red S was
measured at 570nm using a spectrophotometer. To induce chondrogenic
differentiation, 1 10
5 cells were added to a 15ml polypropylene tube and
pelletedbycentrifugation.Thepelletwasculturedat371Cina5%CO 2incubatorin
1ml of chondrocyte differentiation medium (Lonza) for 2 weeks. After 2 weeks, the
roundpelletswereembeddedinparafﬁnandcutinto 3mmsections.For histological
evaluation, the sections were stained with toluidine blue.
Western blotting. Whole-cell protein lysates were extracted with a solution
containing 1% Triton X-100, 20mM Tris HCl (pH 8), 137mM NaCl, 10% glycerol,
and 2mM EDTA (Sigma-Aldrich). Nuclear and cytoplasmic lysates were extracted
using NE-PER reagents (Thermo, Rockford, IL, USA). The protein concentrations
were determined using a DC assay kit (Bio-Rad, Hercules, CA, USA), and proteins
were separated by 10% SDS-polyacrylamide gel electrophoresis. The separated
proteinswerethentransferredtonitrocellulosemembranesat100Vand350mAfor
2h, and probed using the following primary antibodies: b-CATENIN (number 9562;
Cell Signaling Technology Inc, Danvers, MA, USA), p-b-CATENIN (number 9561;
Cell Signaling Technology Inc.), and b-ACTIN (number 3700; Cell Signaling
Technology Inc.). Secondary antibodies were used according to the manufacturer0s
instructions. Secondary-antibody binding was detected using an enhanced
chemiluminescence detection kit (Amersham, Piscataway, NJ, USA) according to
the manufacturer0s instructions. Protein levels were normalized to b-ACTIN using
Image J analysis software.
ChIP and luciferase reporter assays. ChIP assays were performed
according to the manufacturer’s protocol (Upstate Biotechnology, Waltham, MA,
USA). Chromatin was immunoprecipitated using rabbit anti-human SOX2
antibodies (number ab15830; Abcam). PCR was performed at a ﬁnal template
dilution of 1:50. The primer sequences used in this study are supplied in
Supplementary Table 1. For the luciferase assays, the DKK1 promoter was cloned
intothepGL3-enhancervector(Promega,Madison,WI,USA),andthepGL3-SV40-
control vector was used as a transfection control. The luciferase reporter assays
were performed according to the manufacturer’s instructions. Brieﬂy, 0.75mgo f
pGL3-enhancer vector containing the DKK1 promoter, or the pGL3-control vector
was transfected using Tfx-50 transfection reagent (Promega) at a 2:1 ratio of Tfx-
50:plasmid per well in a 24-well plate. After 48h incubation, the cells were treated
withBright-Gloreagent(Promega)for2min,andtheluminescenceofthecelllysate
was measured with an inﬁnite M200 pro luminometer (Tecan, Mannedorf,
Switzerland). To conﬁrm the luciferase results, the assay was performed using
mutated constructs. The SOX2 HMG-binding domain recognition site was mutated
with a site-directed mutagenic primer. Brieﬂy, the pGL3-enhancer vector containing
the DKK1 promoter was ampliﬁed with a mutagenic primer and Pfu DNA
polymerase (Qiagen, Hilden, Germany) for 20–25 cycles. The methylated, non-
mutated, parental DNA template in the ampliﬁed product was digested with Dpn-I.
Nicked dsDNA plasmid was transformed into competent cells, and the mutated
plasmid was conﬁrmed by sequencing. The sequences of the mutagenic primers
are supplied in Supplementary Table 1. The TOP/FOP Flash assays were
performed according to the manufacturer’s instructions. The cells were transfected
with 1mg TOP Flash or 0.24mg FOP Flash plasmid (Millipore), with 0.1mg of renilla
luciferase expression plasmid (Millipore) per well, using the Tfx-50 transfection
reagentina24-wellplate.Thecellsweretreatedasindicated,andluciferaseactivity
was measured with the Dual-Luciferase reporter assay system (Promega).
Statisticalanalyses. ThechangeintheCTofthetargetgeneswascalculated
asDCT¼(CT oftargetgenes) (CT of GAPDH).Theratio of thetargetgeneto the
housekeeping gene was calculated and expressed as 2
 DCT. This ratio was then
used to evaluate the expression of each target gene in SOX2-inhibited hUCB–
MSCsandcontrolhUCB–MSCs. Todeterminethechangesingeneexpression,the
normalized gene expression of the target genes in SOX2-inhibited hUCB–MSCs
was divided by the normalized expression of the same target gene in the control
samples.Allexperimentswereconductedintriplicate,andtheresultsareexpressed
as the mean±S.D. Statistical analyses were conducted via analysis of variance,
followed by Duncan’s multiple range tests or Student’s t-test. Po0.05 was
considered to be signiﬁcant.
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